Aimmune Therapeutics, Inc. (NASDAQ:AIMT) – Equities researchers at Cantor Fitzgerald issued their FY2019 earnings per share estimates for Aimmune Therapeutics in a note issued to investors on Monday. Cantor Fitzgerald analyst W. Tanner anticipates that the biotechnology company will earn ($2.17) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $55.00 target price on the stock.

Several other equities analysts also recently issued reports on the stock. BidaskClub downgraded shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. Robert W. Baird assumed coverage on shares of Aimmune Therapeutics in a report on Wednesday, December 20th. They set an “outperform” rating and a $64.00 price objective on the stock. Zacks Investment Research downgraded shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Piper Jaffray Companies upped their price objective on shares of Aimmune Therapeutics from $38.00 to $60.00 and gave the company an “overweight” rating in a report on Tuesday, December 5th. Finally, ValuEngine downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. Aimmune Therapeutics has an average rating of “Buy” and a consensus target price of $55.43.

Shares of Aimmune Therapeutics (NASDAQ:AIMT) traded down $0.38 during trading on Thursday, reaching $36.91. 268,600 shares of the company’s stock were exchanged, compared to its average volume of 371,082. The company has a market capitalization of $1,880.00 and a P/E ratio of -15.77. Aimmune Therapeutics has a fifty-two week low of $15.97 and a fifty-two week high of $40.00.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.09.

A number of large investors have recently modified their holdings of the stock. SG Americas Securities LLC increased its holdings in Aimmune Therapeutics by 10.1% in the 2nd quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock worth $112,000 after buying an additional 499 shares during the period. Legal & General Group Plc increased its holdings in Aimmune Therapeutics by 26.6% in the 2nd quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock worth $160,000 after buying an additional 1,634 shares during the period. American International Group Inc. increased its holdings in Aimmune Therapeutics by 8.1% in the 3rd quarter. American International Group Inc. now owns 23,591 shares of the biotechnology company’s stock worth $585,000 after buying an additional 1,764 shares during the period. Wells Fargo & Company MN increased its holdings in Aimmune Therapeutics by 3.4% in the 3rd quarter. Wells Fargo & Company MN now owns 61,266 shares of the biotechnology company’s stock worth $1,519,000 after buying an additional 2,025 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in Aimmune Therapeutics by 2.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 134,614 shares of the biotechnology company’s stock worth $3,337,000 after buying an additional 3,261 shares during the period. Institutional investors own 73.34% of the company’s stock.

In other news, insider Daniel C. Md Adelman sold 3,283 shares of the company’s stock in a transaction dated Thursday, December 27th. The shares were sold at an average price of $40.00, for a total transaction of $131,320.00. Following the transaction, the insider now owns 3,283 shares in the company, valued at $131,320. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Douglas T. Sheehy sold 47,425 shares of the stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $34.44, for a total transaction of $1,633,317.00. Following the completion of the transaction, the insider now owns 34,300 shares in the company, valued at approximately $1,181,292. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 140,345 shares of company stock worth $5,036,145. Corporate insiders own 24.56% of the company’s stock.

WARNING: “Cantor Fitzgerald Comments on Aimmune Therapeutics, Inc.’s FY2019 Earnings (AIMT)” was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2018/01/04/cantor-fitzgerald-comments-on-aimmune-therapeutics-inc-s-fy2019-earnings-aimt.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Earnings History and Estimates for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.